MedTrace Logo

Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus

NCT02889510 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2021-02-26

Study results available
· View outcomes & findings →

Summary

Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in significant amounts in the lung, it could be hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced pulmonary function

Conditions

Interventions

DRUG

liraglutide

7-week subcutaneous liraglutide once daily

DRUG

placebo

7-week subcutaneous placebo once daily

Sponsors & Collaborators

  • Dynamic Solutions

    collaborator INDUSTRY

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Lecube, Albert, M.D.

    lead INDIV

Principal Investigators

  • Albert Lecube, PhD · Hospital Universitari Arnau de Vilanova de Lleida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-04
Primary Completion
2019-11-18
Completion
2019-12-16

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02889510 on ClinicalTrials.gov